Orforglipron
FOUNDAYO · LY3502970
A non-peptide GLP-1 receptor agonist formulated as a daily tablet rather than an injection, studied for glycemic control in type 2 diabetes and for weight management.
Tracking and educational reference only, on values you enter yourself. Not medical advice or a dosing recommendation.
Regulatory status
FDA approved
The FDA has approved at least one product containing this substance for a specific medical use, which means it has been through the agency review process and carries an approved label. Approval is always for named indications in named populations, so it is not a statement that any other use has been evaluated.
A regulatory status describes paperwork, not safety. An approved compound can still be wrong for a given person, and an unapproved one is neither thereby dangerous nor thereby fine.
Half-life
~29-49 h, oral. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Oral tablet; stored at room temperature in its original container per the label.
References
- FDA label: FOUNDAYO (NDA 220934)
- N Engl J Med 2023: daily oral orforglipron in adults with obesity
- N Engl J Med 2025: orforglipron for obesity treatment
Read the source
Common questions
Orforglipron, answered plainly.
01What is Orforglipron?+
A non-peptide GLP-1 receptor agonist formulated as a daily tablet rather than an injection, studied for glycemic control in type 2 diabetes and for weight management. It is also referred to as FOUNDAYO, LY3502970. It is listed here under GLP-1 / Metabolic as educational reference, which is not a recommendation to use it.
02Is Orforglipron FDA approved?+
FDA approved. The FDA has approved at least one product containing this substance for a specific medical use, which means it has been through the agency review process and carries an approved label. Approval is always for named indications in named populations, so it is not a statement that any other use has been evaluated.
03What is the half-life of Orforglipron?+
~29-49 h, oral. A half-life is an educational pharmacology figure describing how long the body takes to clear half of a substance. It is not a schedule and does not imply one.
04How is Orforglipron stored and handled?+
Oral tablet; stored at room temperature in its original container per the label. Storage conditions come from a manufacturer's own label where one exists, and a compound with no approved label has no agency-reviewed handling instructions at all.
05What vial strengths of Orforglipron are commonly sold?+
Commonly listed vial strengths are 0.8, 2.5, 5.5, 9 mg. A vial strength is a market fact about how a product is packaged. It is not a dose, and it says nothing about how much of anything belongs in any person.
Compare Orforglipron
Related in GLP-1 / Metabolic
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.